We are pleased to announce that our key composition of matter patent for GlyTherix Ltd’s proprietary antibody to GPC-1 is now registered in 20 countries including US, Australia, China and Japan as well as several key European countries.

The company’s IP estate is strong and unique. Watch for more announcements about our other patent families over the coming months.